Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA

We Celebrate 5,000 Scientific Articles @pharmaceuticalintelligence.com – 2016 was a GREAT Year !!!!!

December 19, 2016 by 2012pharmaceutical

We Celebrate 5,000 Scientific Articles @pharmaceuticalintelligence.com – 2016 was a GREAT Year !!!!!

Curator and Open Access Journal Editor-in-Chief: Aviva Lev-Ari, PhD, RN

2.1.5.7

2.1.5.7 We Celebrate 5,000 Scientific Articles @pharmaceuticalintelligence.com – 2016 was a GREAT Year – Record Articles on CRISPR !!!!! Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 2: CRISPR for Gene Editing and DNA Repair

April 30, 2012: Launch Date for 1st Article

December 19, 2016: Date we Celebrate 5,000 Scientific Articles and 1,118,520 e-Readers

For 2016, Our Top Articles by e-Readers Views and Authors are:

These articles and others are in EIGHT e-Books on Amazon.com

Forthcoming SEVEN e-Books in 2016

https://www.linkedin.com/pulse/forthcoming-cover-pages-new-e-books-medicine-from-lev-ari-phd-rn?trk=prof-post

WE ARE ON AMAZON.COM

http://www.amazon.com/dp/B00DINFFYC

http://www.amazon.com/dp/B018Q5MCN8

http://www.amazon.com/dp/B018PNHJ84

http://www.amazon.com/dp/B018DHBUO6

http://www.amazon.com/dp/B013RVYR2K

http://www.amazon.com/dp/B012BB0ZF0

http://www.amazon.com/dp/B019UM909A

http://www.amazon.com/dp/B019VH97LU

BioMedical e-Books e-Series:

Cardiovascular, Genomics, Cancer, BioMed, Patient Centered Medicine

https://pharmaceuticalintelligence.com/biomed-e-books/

2013 e-Book on Amazon.com

Perspectives on Nitric Oxide in Disease Mechanisms, on Amazon since 6/2/12013

http://www.amazon.com/dp/B00DINFFYC

2015 e-Book on Amazon.com

Metabolic Genomics and Pharmaceutics, on Amazon since 7/21/2015

http://www.amazon.com/dp/B012BB0ZF0

Cancer Biology & Genomics for Disease Diagnosis, on Amazon since 8/11/2015

http://www.amazon.com/dp/B013RVYR2K

Genomics Orientations for Personalized Medicine, on Amazon since 11/23/2015

http://www.amazon.com/dp/B018DHBUO6

Milestones in Physiology: Discoveries in Medicine, Genomics and Therapeutics, on Amazon.com since 12/27/2015

http://www.amazon.com/dp/B019VH97LU

Cardiovascular, Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation, on Amazon since 11/30/2015

http://www.amazon.com/dp/B018Q5MCN8

Cardiovascular Diseases, Volume Three: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics, on Amazon since 11/29/2015

http://www.amazon.com/dp/B018PNHJ84

Cardiovascular Diseases, Volume Four: Regenerative and Translational Medicine: The Therapeutics Promise for Cardiovascular Diseases, on Amazon since 12/26/2015

http://www.amazon.com/dp/B019UM909A

Posted in CRISPR/Cas9 & Gene Editing, LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management | Leave a Comment »

Evaluating the Genetic Profiles of Tumor Cells circulating in the Bloodstream could transform Cancer Care: A Blood Test for managing Lung Cancer @Stanford University Medical School

December 19, 2016 by 2012pharmaceutical

Evaluating the Genetic Profiles of Tumor Cells circulating in the Bloodstream could transform Cancer Care: A Blood Test for managing Lung Cancer @Stanford University Medical School

Reporter: Aviva Lev-Ari, PhD, RN

A Legacy of Innovation @Stanford University Medical School

1967

First synthesis of biologically active DNA in test tube
1968

First adult human heart transplant in the United States

Norman Shumway successfully transplants a heart into 54-year-old steelworker Mike Kasperak, who survives for 14 days.
1973

First expression of a foreign gene implanted in bacteria by recombinant DNA methods
1981

First successful human combined heart/lung transplant in the world (fourth attempted worldwide)
1984

Isolation of a gene coding for part of the T-cell receptor, a key to the immune system’s function
1988

Isolation of pure hematopoietic stem cells from mice
2002

First use of gene expression profiling to predict cancer outcomes
2007

Application and expansion of optogenetics, a technique to control brain cell activity with light

SOURCE

http://med.stanford.edu/

Evaluating the Genetic Profiles of Tumor Cells circulating in the Bloodstream could transform Cancer Care: A Blood Test for managing Lung Cancer @Stanford University Medical School

The approach that the team developed could be used to look at mutations in three or four genes, and it requires no more than 2 milliliters of blood — about half a teaspoon. The test can be completed in about five hours, the researcher said, and costs less than $30. For comparison, a single state-of-the art biopsy of lung tissue with DNA sequencing costs about $18,000 and takes as long as three weeks to furnish results. Johnson & Johnson’s CellSearch — another blood test, already approved by the FDA — costs about $900 and takes a week to deliver results.

The researchers created a system for isolating circulating tumor cells from the blood of cancer patients and reading a handful of genes from inside each tumor cell. Thus, they were able to obtain genetic information about the original cancer tumor that resides deep in the lungs without doing a biopsy, which can be dangerous for the patient.

“We are trying to make minimally invasive technology that allows us to continuously monitor one person’s health over time,” said radiology instructor Seung-min Park, PhD, a lead author of the new study, which was published online Dec. 12 in the Proceedings of the National Academy of Sciences. Park shares lead authorship of the study with former Stanford graduate students Dawson Wong, PhD, and Chin Chun Ooi.

A MagSifter chip, shown here fastened to an acrylic holder, can purify circulating tumor cells from the blood of cancer patients.

The MagSifter is an electromagnetic sieve that can be turned on and off. When the MagSifter is on, it pulls the nanoparticle-labeled CTCs from the blood sample and allows the rest of the blood to flow through the sifter. The CTCs pulled from the blood are then deposited into a flat array of tiny wells, each large enough for only one cell. Now the tumor cells are ready for genetic analysis. Each flat of 25,600 wells looks like a miniature muffin tin, with room for a lot of tiny muffins.

SOURCE

http://med.stanford.edu/news/all-news/2016/12/blood-test-could-provide-cheaper-way-to-evaluate-lung-tumors.html

Posted in CANCER BIOLOGY & Innovations in Cancer Therapy, Cancer Genomics, Cancer Informatics, Circulating Tumor Cells (CTC), Genetics & Innovations in Treatment, Genome Biology, Genomic Testing: Methodology for Diagnosis, Liquid Biopsy: Circulating Tumor Cells in Urine and Blood, MagSifter chip, Variation in human protein-coding regions | Leave a Comment »

Vision and Justice: The Art of Citizenship, Harvard Art Museums, August 27, 2016–January 8, 2017, University Teaching Gallery

December 19, 2016 by 2012pharmaceutical

Vision and Justice: The Art of Citizenship, Harvard Art Museums, August 27, 2016–January 8, 2017, University Teaching Gallery

Reporter: Aviva Lev-Ari, PhD, RN

Exhibit of Note in Cambridge, MA

Vision and Justice

Digital publication for “Vision and Justice: The Art of Citizenship” (August 27, 2016–January 8, 2017, Harvard Art Museums) produced by graduate students enrolled in the course taught by Sarah Lewis, Assistant Professor in the Departments of History of Art and Architecture and African and African American Studies, Harvard University, Fall 2016.

SOURCE

http://www.harvardartmuseums.org/visit/exhibitions/5244/vision-and-justice

Posted in Art Exhibits on the Human Condition | Leave a Comment »

Functional Analysis of the Microbiome for Development of Potential Therapeutic Approaches to Weight Regain

December 19, 2016 by 2012pharmaceutical

Functional Analysis of the Microbiome for Development of Potential Therapeutic Approaches to Weight Regain

Reporter: Aviva Lev-Ari, PhD, RN

Transplanting fecal microbes to prevent recurring obesity

Finally, the researchers used these insights to develop new treatments for recurrent obesity. They implanted formerly obese mice with gut microbes from mice that had never been obese. This fecal microbiome transplantation erased the “memory” of obesity in these mice when they were re-exposed to a high-calorie diet, preventing excessive recurrent obesity.

Gut Microbes Contribute to Recurrent ‘Yo-Yo’ Obesity, Study Shows

By Einat Paz-Frankel, NoCamels December 18, 2016

Researchers at Israel’s Weizmann Institute of Science have shown in mice that intestinal microbes – collectively termed the gut microbiome – play an unexpectedly important role in exacerbated post-dieting weight gain, and that this common phenomenon may in the future be prevented or treated by altering the composition or function of the microbiome.

“We’ve shown in obese mice that following successful dieting and weight loss, the microbiome retains a ‘memory’ of previous obesity,” Elinav said in a statement. “This persistent microbiome accelerated the regaining of weight when the mice were put back on a high-calorie diet or ate regular food in excessive amounts.”

http://nocamels.com/2016/12/gut-microbes-recurrent-obesity-diet/

Original Research

Persistent microbiome alterations modulate the rate of post-dieting weight regain

Nature (2016) doi:10.1038/nature20796

Corrected online

28 November 2016

Article tools

Abstract

In tackling the obesity pandemic, significant efforts are devoted to the development of effective weight reduction strategies, yet many dieting individuals fail to maintain a long-term weight reduction, and instead undergo excessive weight regain cycles. The mechanisms driving recurrent post-dieting obesity remain largely elusive. Here, we identify an intestinal microbiome signature that persists after successful dieting of obese mice, which contributes to faster weight regain and metabolic aberrations upon re-exposure to obesity-promoting conditions and transmits the accelerated weight regain phenotype upon inter-animal transfer. We develop a machine-learning algorithm that enables personalized microbiome-based prediction of the extent of post-dieting weight regain. Additionally, we find that the microbiome contributes to diminished post-dieting flavonoid levels and reduced energy expenditure, and demonstrate that flavonoid-based ‘post-biotic’ intervention ameliorates excessive secondary weight gain. Together, our data highlight a possible microbiome contribution to accelerated post-dieting weight regain, and suggest that microbiome-targeting approaches may help to diagnose and treat this common disorder.

SOURCE

http://www.nature.com/nature/journal/vaap/ncurrent/full/nature20796.html

Posted in Gut Microbiome and Obesity, Metabolism, Metabolomics, Microbiologial genetics | Leave a Comment »

21st Century Cures Act reforms to the Food and Drug Administration’s (FDA) regulation of the medical device and pharmaceutical industries – Medical Device Overview: Major FDA Reform Bill Becomes Law

December 19, 2016 by 2012pharmaceutical

21st Century Cures Act reforms to the Food and Drug Administration’s (FDA) regulation of the medical device and pharmaceutical industries – Medical Device Overview: Major FDA Reform Bill Becomes Law

Reporter: Aviva Lev-Ari, PhD, RN

HIGHLIGHTS

The 21st Century Cures Act seeks to expedite development of, and provide priority review for, “breakthrough” devices
The act requires FDA to provide training on the meaning and implementation of the least burdensome review standard, and requires an audit of the results
The act expressly excludes certain categories of medical software from FDA regulation

Major provisions of the act related to medical device regulation found in Subtitle F are listed, below.

President Obama recently signed the 996-page 21st Century Cures Act to implement a variety of reforms to the Food and Drug Administration’s (FDA) regulation of the medical device and pharmaceutical industries.

This alert summarizes the major provisions of the act related to medical device regulation found in Subtitle F.

Section 3051 – Breakthrough Devices

Section 3052 – Humanitarian Device Exemption (HDE)

Section 3053 – Recognition of Standards

Section 3054 – Certain Class 1 and Class II Devices

Section 3055 – Classification Panels

Section 3056 – Institutional Review Board Flexibility

Section 3057 – CLIA Waiver Improvements

Section 3058 – Least Burdensome Device Review

Section 3059 – Cleaning Instructions and Validation Data Requirement

Section 3060 – Clarifying Medical Software Regulation

A copy of the act can be found here.

http://docs.house.gov/billsthisweek/20161128/CPRT-114-HPRT-RU00-SAHR34.pdf

For more information, please contact the Barnes & Thornburg LLP attorney with whom you work or one of the following attorneys in the firm’s Food, Drug & Device Group: Lynn Tyler at (317) 231-7392 or lynn.tyler@btlaw.com; Beth Davis at (404) 264-4025 or beth.davis@btlaw.com; or Alicia Raines Barr at (317) 231-7398 or alicia.rainesbarr@btlaw.com.

Visit us online at www.btlaw.com/food-drug-and-device-law-practices.

SOURCE

http://www.btlaw.com/files/Uploads/Documents/2016%20Alerts/Food,%20Drug%20and%20Device/FDA%20Alert%20-%2021st%20Century%20Cures%20Act.pdf

http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM393978.pdf

News from Technion Integrated Cancer Center (TICC)

December 18, 2016 by 2012pharmaceutical

News from Technion Integrated Cancer Center (TICC)

Reporter: Aviva Lev-Ari, PhD, RN

Technion Integrated Cancer Center, a first-of-its-kind institution that brings together world-class clinical experts, a group of life science researchers led by a Nobel Prize winner, and top-level chemists, physicists and engineers to win the battle against cancer.

The TICC serves as a nexus for the Technion’s five affiliated hospitals that run clinical trials, the Rappaport Faculty of Medicine’s life sciences researchers, the Faculty of Computer Science’s innovations in processing large data sets, the Viterbi Faculty of Electrical Engineering’s and the Faculty of Physics’ development of devices for diagnosis and imaging, and the Faculty of Mathematics’ search for new, more powerful algorithms to quickly and effectively process complex data.

The power of diverse, accomplished researchers and practitioners is essential to advancing our ability to combat cancer.

“We have quite a few ideas about how to combat this disease, but translating those ideas into actual drugs is not easy. We have to determine if the drugs work by finding the right patient population because not all patients will respond to certain drugs. And we need to develop new strategies to determine who those patients are,” Ronai said. “We used to develop the same drugs to attack cancer, but we now know that cancer is complex and heterogeneous. Our drugs need to be smart enough to attack the different elements of each different type of cancer.”

SOURCE

https://americantechniontoday.wordpress.com/2016/11/28/technion-integrated-cancer-center-ticc-turning-big-ideas-into-action/

Chapter 20: Cancer Research @Technion, Israel Institute of Technology

Stephen J. Williams, PhD

Series C: e-Books on Cancer & Oncology

Series C Content Consultant: Larry H. Bernstein, MD, FCAP

VOLUME TWO

Cancer Therapies:

Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery

Authors, Curators and Editors

Larry H Bernstein, MD, FCAP

larry.bernstein@gmail.com

and

Stephen J Williams, PhD

sjwilliamspa@comcast.net

Guest Authors and Curators

Tilda Barliya, PhD, tildabarliya@gmail.com

Demet Sag, PhD, demet.sag@gmail.com

Dror Nir, PhD, dror.nir@radbee.com

Ziv Raviv, PhD zraviv06@gmail.com

Danut Dragoi, PhD, Danut.daa@gmail.com

Evelina Cohn, PhD, ecohn2011@yahoo.com

Aviva Lev-Ari, PhD, RN, avivalev-ari@alum.berkeley.edu

20.1 Recent Breakthroughs in Cancer Research at the Technion, Israel Institute of Technology, 2015

Stephen J. Williams, PhD

20.2 @Technion: Directions in Cancer Research

20.2.1 Medical Breakthrough: Israeli Researcher Predicts Where Cancer Will Spread

Evelina Cohn Budu, PhD

20.2.2 Pancreatic Cancer at the Crossroads of Metabolism

Demet Sag, PhD, CRA, GCP

20.2.3 List of Breakthroughs in Cancer Research and Oncology Drug Development by Awardees of The Israel Cancer Research Fund

Aviva Lev-Ari, PhD, RN

20.2.4 Cancer Labs at School of Medicine @ Technion: Janet and David Polak Cancer and Vascular Biology Research Center

Aviva Lev-Ari, PhD, RN

20.2.5 Immunity and Host Defense – A Bibliography of Research @Technion

Aviva Lev-Ari, PhD, RN

20.2.6 Host – Tumor Interactions during Cancer Therapy – Dr. Yuval Shaked’s Lab @Technion

Aviva Lev-Ari, PhD, RN

20.3 @Technion Deals, Partnerships, and Collaborations

20.3.1 Next-generation Universal Cell Immunotherapy startup Adicet Bio, Menlo Park, CA is launched with $51M Funding by OrbiMed

Aviva Lev-Ari, PhD, RN

20.3.2 Solutions for Multiple Myeloma – a cancer formed by Malignant Plasma Cells: Collaboration of NYU and Technion Integrative Cancer Center

Aviva Lev-Ari, PhD, RN

20.3.3 Biomarkers of Cancer detected by BreathAnalyzer – An Collaborative effort of three Universities

Aviva Lev-Ari, PhD, RN

20.3.4 Technion established the most advanced Center for Structural Biology in Israel

Aviva Lev-Ari, PhD, RN

20.3.5 Technion-Cornell Innovation Institute in NYC: Postdocs keep exclusive license to their IP and take a fixed dollar amount of Equity if the researchers create a Spinoff company

Aviva Lev-Ari, PhD, RN

Posted in CANCER BIOLOGY & Innovations in Cancer Therapy | Leave a Comment »

Translation of whole human genome sequencing to clinical practice: The Joint Initiative for Metrology in Biology (JIMB) is a collaboration between NIST and Stanford University

December 18, 2016 by 2012pharmaceutical

Translation of whole human genome sequencing to clinical practice: The Joint Initiative for Metrology in Biology (JIMB) is a collaboration between the National Institute of Standards & Technology (NIST) and Stanford University.

Reporter: Aviva Lev-Ari, PhD, RN

JIMB’s mission is to advance the science of measuring biology (biometrology). JIMB is pursuing fundamental research, standards development, and the translation of products that support confidence in biological measurements and reliable reuse of materials and results. JIMB is particularly focused on measurements and technologies that impact, are related to, or enabled by ongoing advances in and associated with the reading and writing of DNA.

Stanford innovators and industry entrepreneurs have joined forces with the measurement experts from NIST to create a new engine powering the bioeconomy. It’s called JIMB — “Jim Bee” — the Joint Initiative for Metrology in Biology. JIMB unites people, platforms, and projects to underpin standards-based research and innovation in biometrology.

Genome in a Bottle
Authoritative Characterization of
Benchmark Human Genomes

The Genome in a Bottle Consortium is a public-private-academic consortium hosted by NIST to develop the technical infrastructure (reference standards, reference methods, and reference data) to enable translation of whole human genome sequencing to clinical practice. The priority of GIAB is authoritative characterization of human genomes for use in analytical validation and technology development, optimization, and demonstration. In 2015, NIST released the pilot genome Reference Material 8398, which is genomic DNA (NA12878) derived from a large batch of the Coriell cell line GM12878, characterized for high-confidence SNPs, indel, and homozygous reference regions (Zook, et al., Nature Biotechnology 2014).

There are four new GIAB reference materials available. With the addition of these new reference materials (RMs) to a growing collection of “measuring sticks” for gene sequencing, we can now provide laboratories with even more capability to accurately “map” DNA for genetic testing, medical diagnoses and future customized drug therapies. The new tools feature sequenced genes from individuals in two genetically diverse groups, Asians and Ashkenazic Jews; a father-mother-child trio set from Ashkenazic Jews; and four microbes commonly used in research. For more information click here. To purchase them, visit:

Data and analyses are publicly available (GIAB GitHub). A description of data generated by GIAB is published here. To standardize best practices for using GIAB genomes for benchmarking, we are working with the Global Alliance for Genomics and Health Benchmarking Team (benchmarking tools).

High-confidence small variant and homozygous reference calls are available for NA12878, the Ashkenazim trio, and the Chinese son with respect to GRCh37. Preliminary high-confidence calls with respect to GRCh38 are also available for NA12878. The latest version of these calls is under the latest directory for each genome on the GIAB FTP.

The consortium was initiated in a set of meetings in 2011 and 2012, and the consortium holds open, public workshops in January at Stanford University in Palo Alto, CA and in August/September at NIST in Gaithersburg, MD. Slides from workshops and conferences are available online. The consortium is open and welcomes new participants.

SOURCE

http://jimb.stanford.edu/giab

May 22, 2017

JIMB WORLD METROLOGY DAY SYMPOSIUM

Stanford University

JIMB’s mission is to motivate standards-based measurement innovation to facilitate translation of basic science and technology development breakthroughs in genomics and synthetic biology.

By advancing biometrology, JIMB will push the boundaries of discovery science, accelerate technology development and dissemination, and generate reusable resources.

SOURCE

http://jimb.stanford.edu/

VIEW VIDEO

https://player.vimeo.com/video/184956195?wmode=opaque&api=1″,”url”:”https://vimeo.com/184956195″,”width”:640,”height”:360,”providerName”:”Vimeo”,”thumbnailUrl”:”https://i.vimeocdn.com/video/594555038_640.jpg”,”resolvedBy”:”vimeo”}” data-block-type=”32″>

Squid: Coming to Life—images and video captured the MBL Embryology course between 2007 and 2016. Produced by former course co-director Nipam Patel, UC Berkeley.

December 16, 2016 by 2012pharmaceutical

Squid: Coming to Life—images and video captured the MBL Embryology course between 2007 and 2016. Produced by former course co-director Nipam Patel, UC Berkeley.

Reporter: Aviva lev-Ari, PhD, RN

Posted in Biological Networks, Gene Regulation and Evolution | Leave a Comment »

Technion Integrated Cancer Center (TICC): Turning Big Ideas into Action

December 16, 2016 by 2012pharmaceutical

Technion Integrated Cancer Center (TICC): Turning Big Ideas into Action

Reporter: Aviva Lev-Ari, PhD, RN

NOVEMBER 28, 2016 BY THE AMERICAN TECHNION SOCIETY

www.ats.org/cancer

Technion Integrated Cancer Center (TICC): Turning Big Ideas into Action

Compelling philanthropic initiatives often sound simple.

End child hunger. Educate all people. Spread clean water access. Help earthquake victims. Improve health care. Cure cancer.

But these bold objectives are not simple. These are big, complex ideas requiring tremendous resources that research universities are often best equipped to harness. Philanthropy is one of the key resources needed. We at ATS don’t actually execute these initiatives—but we play the critical role of translating the big ideas into action by connecting the diverse and sometimes disparate groups of people who can accomplish these far-reaching goals together.

In other words, we don’t solve the problem: we enable the Technion to assemble the team that can solve the problem. It’s a subtle but important distinction that was brought to life earlier this month, as we marked the opening of the Technion Integrated Cancer Center, a first-of-its-kind institution that brings together world-class clinical experts, a group of life science researchers led by a Nobel Prize winner, and top-level chemists, physicists and engineers to win the battle against cancer.

(l to r) Prof. Ze’ev Ronai, Co-Director of the TICC; Technion President Professor Peretz Lavie; Yona Yahav, Mayor of Haifa; Distinguished Professor Aaron Ciechanover, Co-Director of the TICC; Prof. Rafi Beyar, Director of the Rambam Healthcare Campus

Cancer is one of the greatest challenges of humankind today. In the U.S. alone, with its population of 300 million people, there are 1.5 million new cancer patients every year, causing 300,000 deaths. When I spoke with TICC Co-Director Ze’ev Ronai, he emphasized that harnessing the power of diverse, accomplished researchers and practitioners is essential to advancing our ability to combat cancer.

SOURCE

https://americantechniontoday.wordpress.com/2016/11/28/technion-integrated-cancer-center-ticc-turning-big-ideas-into-action/

Posted in CANCER BIOLOGY & Innovations in Cancer Therapy | Leave a Comment »

« Newer Posts - Older Posts »

We Celebrate 5,000 Scientific Articles @pharmaceuticalintelligence.com – 2016 was a GREAT Year !!!!!

April 30, 2012: Launch Date for 1st Article

December 19, 2016: Date we Celebrate 5,000 Scientific Articles and 1,118,520 e-Readers

For 2016, Our Top Articles by e-Readers Views and Authors are:

Top Posts for 365 days ending 2016-12-19 (Summarized)

These articles and others are in EIGHT e-Books on Amazon.com

Forthcoming SEVEN e-Books in 2016

WE ARE ON AMAZON.COM

BioMedical e-Books e-Series:

Cardiovascular, Genomics, Cancer, BioMed, Patient Centered Medicine

2013 e-Book on Amazon.com

2015 e-Book on Amazon.com

Share this:

Like this:

Evaluating the Genetic Profiles of Tumor Cells circulating in the Bloodstream could transform Cancer Care: A Blood Test for managing Lung Cancer @Stanford University Medical School

A Legacy of Innovation @Stanford University Medical School

First synthesis of biologically active DNA in test tube

First adult human heart transplant in the United States

First expression of a foreign gene implanted in bacteria by recombinant DNA methods

First successful human combined heart/lung transplant in the world (fourth attempted worldwide)

Isolation of a gene coding for part of the T-cell receptor, a key to the immune system’s function

Isolation of pure hematopoietic stem cells from mice

First use of gene expression profiling to predict cancer outcomes

Application and expansion of optogenetics, a technique to control brain cell activity with light

Evaluating the Genetic Profiles of Tumor Cells circulating in the Bloodstream could transform Cancer Care: A Blood Test for managing Lung Cancer @Stanford University Medical School

Share this:

Like this:

Vision and Justice: The Art of Citizenship, Harvard Art Museums, August 27, 2016–January 8, 2017, University Teaching Gallery

Share this:

Like this:

Functional Analysis of the Microbiome for Development of Potential Therapeutic Approaches to Weight Regain

Gut Microbes Contribute to Recurrent ‘Yo-Yo’ Obesity, Study Shows

Share this:

Like this:

21st Century Cures Act reforms to the Food and Drug Administration’s (FDA) regulation of the medical device and pharmaceutical industries – Medical Device Overview: Major FDA Reform Bill Becomes Law

A copy of the act can be found here.

Other related articles published in this Open Access Online Scientific Journal include the following:

Share this:

Like this:

News from Technion Integrated Cancer Center (TICC)

Other related articles published in this Open Access Online Scientific Journal include the following:

Chapter 20: Cancer Research @Technion, Israel Institute of Technology

Series C Content Consultant: Larry H. Bernstein, MD, FCAP

VOLUME TWO

Cancer Therapies:

Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery

20.1 Recent Breakthroughs in Cancer Research at the Technion, Israel Institute of Technology, 2015

20.2 @Technion: Directions in Cancer Research

20.3 @Technion Deals, Partnerships, and Collaborations

Share this:

Like this:

Translation of whole human genome sequencing to clinical practice: The Joint Initiative for Metrology in Biology (JIMB) is a collaboration between the National Institute of Standards & Technology (NIST) and Stanford University.

Genome in a Bottle Authoritative Characterization of Benchmark Human Genomes

Other related articles published in this Open Access Online Scientific Journal include the following:

Share this:

Like this:

Squid: Coming to Life—images and video captured the MBL Embryology course between 2007 and 2016. Produced by former course co-director Nipam Patel, UC Berkeley.

Share this:

Like this:

Technion Integrated Cancer Center (TICC): Turning Big Ideas into Action

Share this:

Like this:

11th annual BioPharma & Healthcare Summit, USA-India Chamber of Commerce, May 18, 2017 @ Marriott Cambridge, Massachusetts

Online registration is available at the web site

Share this:

Like this:

Follow Blog via Email

Recent Posts

Archives

Categories

Meta

Genome in a Bottle
Authoritative Characterization of
Benchmark Human Genomes